Abstract:We showed the development of a novel pyrrolopyrimidine derivative as an anti‐glioma agent via potent inhibition of EGFR‐TK. The results suggest that the most potent EGFR‐TK inhibitor, compound 4i, significantly inhibited the proliferation of both wild‐type and mutant glioblastoma cells. It also promoted apoptosis of glioblastoma cells by cell cycle arrest at the G2 phase, possibly via attenuating EGFR‐TK. Glioma is an aggressive type of brain malignancy responsible for significant morbidity and mortality. In the current scenario, epidermal growth factor receptor (EGFR) kinases targeted therapy showed significant benefits in glioma patients. Therefore, in the present study, we intend to investigate the anti‐glioma potential of a novel class of pyrazole‐pyrrolopyrimidine derivatives and their mechanism of action. The compounds will be synthesized in a straight‐forward synthetic route in excellent yields and subsequently tested for EGFR kinase inhibition. The compounds showed a diverse range of inhibitory activity against EGFR (IC50 = 3.4–873.2 nM). With an IC50 of 1.5 nM, compound 4i was determined to be the most effective EGFR inhibitor, even superior to the standard erlotinib (IC50 2.3 nM). Among them, the three most potent compounds (4i, 4j, and 4k) were further subjected to the anticancer activity against the panel of various cancer cell lines MCF‐7 (breast cancer), A549 (lung cancer), U87 (glioblastoma cell)‐EGFR‐Wild Type, U87 (mutant glioblastoma cells) EGFR‐mutant cell, MCF‐12A (normal cells). The compound 4i showed the most potent activity against glioblastoma cells as compared to other cancer cells. The effect of compound 4i was also studied on the apoptosis of U87 cells, where it showed induction of apoptosis in a concentration‐dependent manner. It also showed inhibition of the G2/M cell cycle phase of U87 cells. Our study demonstrated the development of novel pyrazole‐pyrrolopyrimidine derivatives as a novel class of anti‐glioma agents.

Synthesis and biological evaluation of celastrol derivatives as potential anti-glioma agents by activating RIP1/RIP3/MLKL pathway to induce necroptosis

Design, synthesis of novel celastrol derivatives and study on their antitumor growth through HIF-1α pathway

Synthesis and Biological Evaluation of Celastrol Derivatives with Improved Cytotoxic Selectivity and Antitumor Activities

Celastrol Suppresses Glioma Vasculogenic Mimicry Formation and Angiogenesis by Blocking the PI3K/Akt/mTOR Signaling Pathway

Design and Synthesis of Novel Celastrol Derivatives as Potential Anticancer Agents against Gastric Cancer Cells

Structure-activity relationship study of Pseudellone C as anti-glioma agents by targeting TNF/TNFR signaling pathway

Synthesis and Biological Evaluation of Celastrol Derivatives as Potential Immunosuppressive Agents

Enhanced Proliferation Inhibition and Apoptosis in Glioma Cells Elicited by Combination of Irinotecan and Imatinib

Celastrol targets proteostasis and acts synergistically with a heat-shock protein 90 inhibitor to kill human glioblastoma cells

Design, synthesis, and evaluation of antitumor activity of novel C‐6 sulfhydryl‐substituted and 20‐substituted derivatives of celastrol

Synthesis, computational docking and biological evaluation of celastrol derivatives as dual inhibitors of SERCA and P-glycoprotein in cancer therapy

Synthesis of a celastrol derivative as a cancer stem cell inhibitor through regulation of the STAT3 pathway for treatment of ovarian cancer

Novel 4-Aryl-4H-chromene derivative displayed excellent in vivo anti-glioblastoma efficacy as the microtubule-targeting agent

Celastrol Induces Apoptosis and Autophagy Via the ROS/JNK Signaling Pathway in Human Osteosarcoma Cells: an in Vitro and in Vivo Study

Novel terpestacin derivatives with l-amino acid residue as anticancer agents against U87MG-derived glioblastoma stem cells

Synthesis of 3- and 29-Substituted Celastrol Derivatives and Structure-Activity Relationship Studies of Their Cytotoxic Activities.

TRAIL and Celastrol Combinational Treatment Suppresses Proliferation, Migration, and Invasion of Human Glioblastoma Cells via Targeting Wnt/β-catenin Signaling Pathway

Design, Synthesis, and Bioactivity Evaluation of Novel Rosin Diterpenoid Derivatives as Potential Anti‐glioma Agents

NF-Kappa B Modulation Is Involved in Celastrol Induced Human Multiple Myeloma Cell Apoptosis

ML162 derivatives incorporating a naphthoquinone unit as ferroptosis/apoptosis inducers: Design, synthesis, anti-cancer activity, and drug-resistance reversal evaluation

Design and discovery of novel pyrazole‐pyrrolopyrimidine derivatives as anti‐glioma agents via promoting apoptosis, inhibiting cell cycle and EGFR‐TK